Curevac 2025 Q2 Earnings Narrowed Losses Amid Revenue Decline

Curevac (CVAC) reported its fiscal 2025 Q2 earnings on August 15, 2025. The results showed a sharp decline in revenue and continued net losses, though losses were slightly narrower compared to the prior year. The company provided no quantitative guidance for the remainder of the year but emphasized ongoing investment in its mRNA platform and strategic collaborations.

Curevac's total revenue for Q2 2025 plummeted by 91.4% to $1.25 million, significantly below the $14.44 million recorded in the same period in 2024. The modest revenue was driven by several key segments, with the GSK collaboration contributing $186,000 and the CRISPR segment bringing in $1.06 million. These figures highlight the company’s limited top-line performance despite continued partnerships.

The company reported an improvement in its bottom line, narrowing its net loss to $59.56 million in Q2 2025, a 17.9% reduction from the $72.54 million loss in the prior-year quarter. On a per-share basis, the loss narrowed to $0.26 from $0.32, representing an 18.8% improvement. Despite these modest gains, CureVac remains unprofitable, having posted losses for seven consecutive years during the same period.

Curevac’s stock price showed minimal movement, closing down 0.00% for the day but up 0.74% for the week. Month-to-date, the stock was also flat. The post-earnings trading strategy of buying CureVac shares 30 days after a quarter-over-quarter revenue increase proved ineffective. This strategy underperformed significantly with a negative excess return of -50.57%, a CAGR of 0.07%, and a Sharpe ratio of 0.00, indicating no risk-adjusted returns. The maximum drawdown was 0.00%, suggesting the strategy neither gained nor lost capital.

CureVac’s CEO, Alexander Zehnder, highlighted the company’s progress in its RNA technology platform and ongoing collaborations, including the resolution of the patent litigation with Pfizer/BioNTech. He expressed cautious optimism about the pipeline’s potential to deliver transformative medicines while reiterating the company’s focus on operational efficiency and strategic partnerships.

The company did not provide specific financial guidance for the remainder of 2025. Instead, it emphasized its commitment to advancing its mRNA-based therapeutics and vaccines and strengthening its intellectual property position.

Additional News
On the same day as Curevac’s earnings report, the Punch newspaper highlighted several Nigerian news stories. Among them, the Independent National Electoral Commission (INEC) staff and a politician were caught with a significant amount of cash in Ogun State, raising concerns about electoral integrity. Additionally, a sex trafficking ring between Lagos and Ghana was dismantled, and 47 suspected internet fraudsters were arrested in Edo State. In politics, a former federal lawmaker joined the African Democratic Congress (ADC), and by-elections were underway in several constituencies, with low voter turnout reported in some areas.